Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture

Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.

Amplia Therapeutics has completed the first large-scale, GMP-compliant manufacture of narmafotinib, producing about 13 kilograms of active pharmaceutical ingredient and successfully transitioning production from an R&D setting to a commercial-ready environment. The scale-up, achieved in collaboration with a contract development and manufacturing partner, has generated cost efficiencies and ensures sufficient drug supply to support Amplia’s ongoing and planned pancreatic cancer trials and other studies, marking a key step toward Phase 3 readiness and strengthening the company’s clinical development pipeline and future registrational strategy.

The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.

More about Amplia Therapeutics

Amplia Therapeutics Limited is an Australian pharmaceutical company developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors targeting cancer and fibrosis, with a particular focus on fibrotic cancers such as pancreatic and ovarian cancer as well as chronic diseases like idiopathic pulmonary fibrosis. Its lead candidate, narmafotinib (AMP945), is a highly potent and selective FAK inhibitor being evaluated in combination with standard chemotherapies in advanced pancreatic cancer, where it has already shown improved response rates and progression-free survival compared with historical benchmarks.

Average Trading Volume: 727,484

Technical Sentiment Signal: Buy

Current Market Cap: A$79.53M

For a thorough assessment of ATX stock, go to TipRanks’ Stock Analysis page.